Search

Displaying results 4961 - 4970 of 5897 in total
  1. Drug

    SAR443122

    go.drugbank.com/drugs/DB16492
    Investigational

    SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy.

  2. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    It is used to treat dermatological infections.[A228063]

  3. Drug

    VIR-5818

    go.drugbank.com/drugs/DB28582
    Investigational

    VIR-5818 is under investigation in clinical trial NCT05356741 (To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants

  4. Drug

    Ammonium molybdate

    go.drugbank.com/drugs/DB11128
    Investigational

    It is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN).

  5. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

  6. Drug

    Galidesivir

    go.drugbank.com/drugs/DB11676
    Investigational

    [L12039,L12084] Phase 1 clinical trials have begun to determine the safety of this drug in humans.

  7. Drug

    Etizolam

    go.drugbank.com/drugs/DB09166
    Investigational

    Etizolam is a thienodiazepine which is chemically related to benzodiazepine (BDZ) drug class; it differs from BDZs in having a benzene ring replaced with a thiophene ring.

    Synonyms: 4-(o-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine
  8. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193]

  9. Drug

    Pegsitacianine

    go.drugbank.com/drugs/DB19098
    Investigational

    Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence

  10. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.